Double-J stent-related lower urinary tract symptoms: a prospective randomized trial of mirabegron, solifenacin, tamsulosin, and tadalafil and their combinations

BACKGROUND: Clinical use of ureteral stents may lead to associated symptoms comparable to overactive bladder and lower urinary tract symptoms (LUTS). This study examined the effectiveness of mirabegron, solifenacin, tamsulosin, and tadalafil and their combinations in patients with LUTS linked to double-J stents, divided into seven treatment groups.METHODS: Consecutive random sampling was used to identify 161 people with LUTS for this double-blind randomized clinical research. Mirabegron 50 mg (group A), solifenacin 5 mg (group B), tamsulosin 0.4 mg (group C), tadalafil 10 mg (group D), mirabegron 25 mg+solifenacin 5 mg (group E), tamsulosin 0.4 mg+solifenacin 5 mg (group F), and placebo (group G) were given to patients in a 1:1 ratio. The Ureteral Stent Symptoms Questionnaire was used to compare treatment outcomes across six indices on days 7, 14, 21, and 28 post ureteral stent insertion (pain and urinary symptoms, general health conditions, sexual matters, working performance, and other problems). The data were analyzed using ANOVA, and significance was determined using a P value cutoff of 0.05.RESULTS: The combination of tamsulosin and solifenacin worked better to treat difficulties with working performance, sexual matters, and additional problems. Tadalafil performed better than other drugs for pain symptoms and general health conditions.CONCLUSIONS: LUTS complaints were reduced in all seven therapy groups. However, the combination of tamsulosin and solifenacin and tadalafil solo therapy were superior to others.